Beyond glasses: FDA approval of VIZZ (aceclidine) transforming presbyopia management

Introduction, epidemiology, and pathophysiology

Presbyopia, derived from the Greek words for “old eye,” is characterized by the progressive inability to focus on near objects. This occurs because of age-related loss of accommodative capacity due to decreased elasticity of the crystalline lens and reduced efficiency of the ciliary muscle^[1,2]. Functionally, the eye loses its ability to rapidly alter the lens curvature, leading to blurry near vision, headaches, and eye strain, particularly under conditions of low illumination[2]. It typically becomes symptomatic in the mid-40s and, by age 50, virtually all adults exhibit some degree of near-blur. About 85% of individuals over 40 require near correction[3]. Globally, an estimated 1.8 billion people had presbyopia in 2015, and this number is projected to exceed 2.1 billion by 2030^[2,3]. The burden is substantial: roughly 128 million U.S. adults (about half of the 40 + population) are affected^[4,5], and unmet need remains high, especially in underserved regions. Uncorrected presbyopia profoundly impairs daily activities (difficulty reading fine print, eye strain, headaches) and quality of life[3]. As life expectancy rises, the societal impact of this near-vision deficit is growing.

Presbyopia’s pathophysiology centers on progressive stiffening of the crystalline lens. The lens loses elasticity and enlarges with age, diminishing its ability to change shape for near focus^[2,6]. Although earlier theories invoked ciliary muscle weakness, evidence now strongly favors lens rigidity as the primary mechanism[3]. The net effect is a reduced “amplitude of accommodation” such that patients cannot achieve the refractive power needed for near tasks.

This editorial has been written in line with the TITAN (Transparency In The reporting of Artificial Intelligence) Guidelines 2025[7].

Traditional management approaches

Conventional presbyopia corrections all compensate for lost accommodation rather than reverse its cause. These include spectacles (reading glasses, bifocals, progressives), contact lenses (single-vision or multifocal), and various surgical options (monovision LASIK or PRK, corneal inlays, multifocal/extended depth-of-focus intraocular lenses, and even scleral expansion procedures)[8]. While optical appliances are widely available and effective, they impose limitations. For example, multifocal or progressive glasses often induce peripheral blur and a restricted visual field, which has been linked to increased fall risk in older adults[3].

Multifocal contact lenses can restore near vision but may be impractical for some presbyopes due to age-related dry eye and manual dexterity issues[3]. Surgical interventions can reduce dependence on spectacles, but they carry risks (infection, inflammation, dry eye, dysphotopsias) and often still leave patients requiring reading glasses for fine print^[3,9]. None of these measures addresses the underlying lens sclerosis. Across all modalities, potential side effects such as glare, halos, and reduced distance visual acuity (DVA) should be considered.

In short, current standard corrections manage the symptom of blurred near vision but not its biological cause^[3,9]. Dependence on corrective lenses remains a major frustration; surveys show that reliance on reading glasses is a leading contributor to reduced quality of life in presbyopes[3].

Pharmacologically, options were limited until recently. A novel symptomatic approach emerged in 2021 when the FDA approved pilocarpine hydrochloride 1.25% (VUITY) – the first eyedrop for presbyopia in the U.S[10]. Pilocarpine is a nonselective muscarinic agonist that constricts the pupil, creating a pinhole-like increase in depth-of-field. As little as 15 minutes after instillation, many patients gain 3 or more lines of near acuity, with effect peaking at about 1 hour and lasting roughly 4–6 hours^[10,11]. Phase 3 GEMINI trials showed statistically significant improvement in low-light near vision without loss of distance acuity[10]. Common side effects were mild (headache, transient brow ache, or eye redness)[10]. Notably, some patients reported transient blurred distance vision and reduced contrast sensitivity, particularly in dim light[11].

Other pilocarpine and miotic formulations have been explored (low-dose pilocarpine 0.4% [QLOSI/CSF-1], combined carbachol/brimonidine drops [Brimochol], etc)[11], as have multi-drug “FOV” cocktails (e.g., pilocarpine + NSAID) and lens-softening agents (lipoic acid esters, UNR844)[9]. However, none of these have yet demonstrated a truly breakthrough effect. The bottom line is that a large clinical unmet need remains for a safer, longer-lasting pharmacologic presbyopia therapies.

FDA approval of VIZZ (aceclidine 1.44%)

In July 2025, Lenz Therapeutics announced that the FDA had approved its once-daily eye drop VIZZ (aceclidine ophthalmic solution 1.44%) for adult presbyopia^[4,5,12]. Aceclidine is a decades-old cholinergic drug (marketed in Europe in the 1970s as a glaucoma agent)[13], now reformulated to exploit its potent miotic effects. Lenz submitted a New Drug Application (LNZ100) in August 2024, which the FDA accepted in October 2024 based on comprehensive Phase 3 data[5]. The pivotal CLARITY program consisted of three randomized, double-masked trials: CLARITY 1 and 2 (n = 466 each, 42-day treatment) and CLARITY 3 (n = 217, 6-month safety extension)[5]. These studies consistently met all primary and secondary endpoints. In treated eyes, near vision improved significantly: many subjects gained ≥3 lines on the near visual acuity chart within 30 minutes of one drop, and these gains persisted for up to ~10 hours^[5,11].

The FDA noted that CLARITY trial formulations used 1.75% aceclidine, while the marketed product contains 1.44%; safety and efficacy data are considered largely translatable based on pharmacodynamic modeling and observed therapeutic window. The FDA thus recognized VIZZ as the “first and only” aceclidine-based drop for presbyopia, and the first once-daily drop showing up to 10-hour efficacy^[4,5].

Mechanism of action and formulation advantages

Aceclidine’s appeal lies in its “pupil-selective” action. Unlike pilocarpine and carbachol, aceclidine binds preferentially to muscarinic receptors on the iris sphincter with minimal effect on the ciliary muscle^[4,11]. In practice, VIZZ causes a sub-2 mm pupil (“pinhole”) that markedly extends depth of focus, but without causing an accommodative spasm or a fixed near-state. Clinically, patients experience improved near vision without a myopic shift in refractive error^[4,5]. This selective mechanism allows higher potency: in CLARITY trials, the median pupil diameter under treatment was ~ 1.8 mm. By comparison, pilocarpine 1.25% (VUITY) typically achieves only ~ 2.7–3 mm pupils after a few hours, and may induce transient blurred distance vision[11]. The practical result is duration: VIZZ maintains its miotic effect for about 10 hours[5] (indeed, 40% of subjects in trials had meaningful near benefit through 10 hours)[11], whereas Vuity’s effect subsides by 6–8 hours and VIZZ’s selective miotic mechanism minimizes DVA reduction, though some patients report mild dim vision under low illumination.

VIZZ is formulated as a buffered aqueous solution (pH-adjusted for comfort) with a concentration (1.44%) optimized for daily dosing. As a new chemical entity in the U.S., aceclidine adds diversity to the drug armamentarium[4]. In summary, VIZZ’s key advantages over earlier drops are its once-daily convenience, longer duration (≈10 h), and its minimal impact on distance vision, attributable to the pupil-selective mechanism.^[4,5]

Clinical trial results and safety profile

The CLARITY trials demonstrated both efficacy and tolerability. By pooled analysis, roughly 70–75% of VIZZ-treated eyes achieved a gain of three or more lines of near acuity, versus only ~ 10–15% with placebo[11]. The improvement was rapid (measurable at 30 minutes) and robust across lighting conditions. The treatment effect was remarkably reproducible: CLARITY-1 and -2 showed nearly identical outcomes. Importantly, no subject experienced any serious treatment-related adverse event in over 30,000 cumulative patient-days on VIZZ^[5,11]. The most common side effects were mild and transient. In CLARITY, instillation-site discomfort (burning/tingling) occurred in ~ 20% of patients; mild transient dimness or blurring of vision was reported in ~ 16%; and headache (classically from miotic action) in about 13%[5]. Conjunctival or ocular hyperemia was seen in <10%. Virtually all reactions were described as mild and resolved within minutes to hours without sequelae[5]. Notably, unlike with pilocarpine, no consistent myopic shift or accommodative spasm was observed[4]. Thus, the overall safety profile is favorable: typical ocular side effects (tiny pupil, glare in very low light at peak miosis) were anticipated, while systemic or inflammatory issues were negligible.

Implications for practice

The approval of VIZZ has immediate clinical significance. For eye care providers, it adds a new modality: a simple drop to offer patients frustrated by glasses or contacts. The ideal candidates are presbyopes (40s–60s) who desire occasional near-vision boost – for example, for computer work, reading, or hobbies – without committing to permanent surgical changes. The once-daily regimen is straightforward (e.g., instill each morning), and the 10-hour duration covers most daytime activities. Because VIZZ is approved for both eyes, it can be used binocularly (unlike some monovision surgeries), preserving binocular vision and reading comfort.

This paradigm is already influencing standards of care. As one presbyopia specialist noted, an effective drop like VIZZ represents a “disruptive paradigm shift” in treatment options[5]. It is reasonable to anticipate that pharmacologic therapy will quickly join lenses and surgery in the presbyopia treatment algorithm. Patients previously reliant on reading glasses can try a drop-based approach, and those already using glasses may find partial replacement of their reading spectacles. In a sense, VIZZ blurs the line between optical and medical correction: it creates a small-aperture lens effect pharmacologically. In the clinic, practitioners should counsel patients on setting expectations (mild side effects and a small pupil) and ensure appropriate ophthalmic evaluation (since underlying eye disease can affect results).

Economic and accessibility considerations will shape VIZZ’s uptake. Price and insurance coverage will determine how widely and how early in the course it is used. Nevertheless, even if initially adopted by early presbyopes or those with progressive burden, VIZZ could reduce the overall glasses dependence in the population. Over time, it may become routine to discuss drop therapy when first diagnosing presbyopia. At a minimum, VIZZ offers a non-invasive, reversible alternative that was not previously available.

Future directions and broader impact

The success of VIZZ underscores a broader trend: pharmacologic presbyopia therapy is now a viable field of innovation. Several companies have similar programs. For example, a low-concentration pilocarpine drop (Orasis’ CSF-1/QLOSI, 0.4%) recently reported positive Phase III results, and a preservative-free formulation is awaiting its launch[14]. Combination drops (carbachol + brimonidine) and novel delivery systems (Eyenovia’s pilocarpine micro-jet spray) are in late-stage development. In contrast, efforts to soften the lens have been more challenging: Novartis’ trial of lipoic acid choline ester (UNR844/EV06) did not meet its primary endpoints[11]. It remains to be seen whether lens-softening or true accommodative restoratives will ever succeed.

Clinically, VIZZ’s availability may spur greater screening and earlier treatment of presbyopia, especially in patients who may not seek other interventions. It will also be interesting to observe whether combination therapies emerge—for example, using both a miotic drop and a lens-softener concurrently, or coupling VIZZ with low-dose adrenergic antagonists to tailor the pupil size.

Ultimately, VIZZ’s approval is a proof of concept: a topical agent can significantly improve near vision in a broad population. This will likely accelerate research into presbyopia pharmacotherapy. Other potential innovations include longer-acting formulations (e.g., sustained-release rings or injections), advanced molecules targeting lens proteins, or even gene-based approaches. In the near term, clinicians should remain aware of the growing “ophthalmic gym bag” of drops for presbyopia, of which VIZZ is a pioneering example.

Conclusion

Presbyopia has traditionally been managed with bulky glasses, contact lenses, or invasive surgery, leaving many patients unsatisfied. The FDA approval of VIZZ (aceclidine 1.44% ophthalmic solution) marks a watershed moment: for the first time, a pharmacologic therapy provides a proven, once-daily improvement in near vision. VIZZ’s novel mechanism yields strong near-vision gains (up to 10 hours) with minimal compromise of distance vision, and its safety profile is reassuring. In practice, VIZZ will become an important addition to the presbyopia armamentarium, addressing a large patient population that has long awaited an alternative to corrective lenses. More broadly, this milestone heralds a new era in presbyopia care. Pharmacologic drops are poised to complement traditional approaches, offering patients greater choice and providing providers with new tools. As clinical experience with VIZZ grows and new agents emerge, the standard of care for age-related near vision is set to evolve significantly.

Ethics approval

Not required for this study.

Consent

Not required.

Source of funding

None declared.

Conflicts of interest

None declared.

Research registration unique identifying number (UIN)

Not applicable.

Guarantor

Mohsin Raza.

Peer and provenance statement

Not commissioned.

Author contributions

All the authors were involved in manuscript preparation, review of literature and final approval of the manuscript. S.M.R.B.: Conceptualization, Data Curation, Project administration, Validation, Writing – original draft, Writing – review & editing. H.M., G.A., M.A., M.R.: Validation, Visualization, Writing – original draft, Writing – review & editing.